Key Points
- Theravance Biopharma SVP Rhonda Farnum sold 13,314 shares at an average price of $17.03, totaling approximately $226,737. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving her with 213,476 shares.
- TBPH shares opened at $17.04, with a 52-week range of $13.08 to $21.03 and a market capitalization of approximately $884.7 million.
- The company recently missed quarterly earnings and revenue estimates, while analysts maintain a consensus “Hold” rating with an average price target of $19.40.
Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $17.03, for a total value of $226,737.42. Following the sale, the senior vice president owned 213,476 shares in the company, valued at approximately $3,635,496.28. This represents a 5.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Theravance Biopharma Price Performance
TBPH stock opened at $17.04 on Friday. Theravance Biopharma, Inc. has a 1-year low of $13.08 and a 1-year high of $21.03. The business has a fifty day moving average price of $16.96 and a 200-day moving average price of $16.40. The stock has a market capitalization of $884.72 million, a P/E ratio of 16.87 and a beta of 0.25.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The business had revenue of $20.73 million for the quarter, compared to analysts' expectations of $22.49 million. As a group, analysts anticipate that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in TBPH. Caitong International Asset Management Co. Ltd raised its position in shares of Theravance Biopharma by 51.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 1,408 shares during the period. First Trust Advisors LP boosted its holdings in Theravance Biopharma by 19.5% in the 1st quarter. First Trust Advisors LP now owns 18,959 shares of the biopharmaceutical company's stock worth $308,000 after buying an additional 3,099 shares during the period. SG Americas Securities LLC increased its stake in Theravance Biopharma by 25.8% in the 1st quarter. SG Americas Securities LLC now owns 18,256 shares of the biopharmaceutical company's stock worth $296,000 after buying an additional 3,747 shares in the last quarter. Wellington Management Group LLP raised its holdings in Theravance Biopharma by 3.4% during the second quarter. Wellington Management Group LLP now owns 113,481 shares of the biopharmaceutical company's stock valued at $1,929,000 after acquiring an additional 3,781 shares during the period. Finally, Quantinno Capital Management LP lifted its position in shares of Theravance Biopharma by 32.9% in the first quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company's stock valued at $293,000 after acquiring an additional 4,463 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
TBPH has been the subject of a number of research analyst reports. Weiss Ratings upgraded shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, August 17th. HC Wainwright cut shares of Theravance Biopharma from a "buy" rating to a "neutral" rating and raised their target price for the stock from $15.00 to $17.00 in a report on Tuesday, July 7th. BTIG Research downgraded shares of Theravance Biopharma from a "buy" rating to a "neutral" rating in a research report on Monday, June 29th. Zacks Research lowered shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 7th. Finally, JonesTrading downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Monday, June 29th. Eight research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and an average price target of $19.40.
Read Our Latest Research Report on Theravance Biopharma
Theravance Biopharma Company Profile
(
Get Free Report)
Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company's work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.
Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
